The International Eczema Council (IEC) created this guide to sessions and posters that address atopic dermatitis. Because scheduling changes may occur, IID attendees should reference on-site signage, the program book, and iid2018.org for the most current information.

### SYMPOSIA AND CONCURRENT SYMPOSIA

**WEDNESDAY, MAY 16, 2018**

**INTERNATIONAL ECZEMA COUNCIL (IEC) SYMPOSIUM**

**Phenotype-Genotype Correlations and Personalized Medicine in Atopic Dermatitis**

Noon–3 pm in Butler

12:05 – 12:30 pm: **Genetic mechanisms of skin barrier failure in AD.** Wilson Liao, San Francisco, CA

12:35 – 1:00 pm: **Genetic mechanisms in AD.** Stephan Weidinger, Kiel, Germany

1:05 – 1:30 pm: **Skin barrier, immune dysregulation and itch – therapeutic implications.** Kenji Kabashima, Kyoto, Japan

1:35 – 2:00 pm: **Differences in immune dysregulation in various AD phenotypes and the road to personalized medicine.** Emma Guttman-Yassky, New York, NY

2:15 pm:

- **Abstract #555:** Integrating serum and skin biomarkers to assess disease extent beyond clinical scores, advancing precision therapeutics. Kunal Malik et al., Mount Sinai, New York, NY
- **Abstract #559:** ASN002 a dual oral inhibitor of JAK/SYK signaling improves clinical outcomes and associated cutaneous inflammation in moderate-to-severe atopic dermatitis patients. Emma Guttman et al., Mount Sinai, New York, NY
- **Abstract #1446:** Atopic Cytokines IL4/13 Perturb iPSC-Derived Itch-Specific Sensory Neurons. Zongyou Guo et al., Columbia University, New York, NY
- **Abstract #1039:** Skin microbiome profiles of atopic dermatitis patients segregate into two community composition types that are stable before and after therapy. John Common et al., A*STAR, Singapore

**INTERNATIONAL PSORIASIS COUNCIL**

**The Psoriatic Disease Mechanistic Scenarios**

1–4:30 pm in St. John’s 28-29

3:25 pm:

- **Abstract #432:** Investigating a causal relationship between body mass index and inflammatory skin disease using mendelian randomization. Sara Brown, MD FRCPE, Dundee, Scotland
• Abstract #764: miR-146a and miR-146b regulate members of the IL-1 family in human primary keratinocytes. 
Helen Hermann, MSc, Estonia

THURSDAY, MAY 17, 2018
PLENARY SESSION I
8:45–9:45 am in Gatlin D-E
9:33 am:
Abstract #426: Clinical improvement in atopic dermatitis following autologous application of microbiome therapy targeting Staphylococcus aureus.

CONCURRENT MINI-SYMPOSIUM 2
Clinical Research: Epidemiology of Skin Diseases
3:15–5:45 pm in Panzacola F-1/2
3:27 pm:
Abstract #247: Patterns of atopic eczema activity in childhood and adulthood: Results from 2 national prospective British cohort studies.
3:51 pm:
Abstract #372: Severe and predominantly active adult atopic eczema is a risk factor for cardiovascular disease: a UK population-based cohort study.

CONCURRENT MINI-SYMPOSIUM 3
Innate Immunity, Microbiology, Inflammation
3:15–5:45 pm in Gatlin D-E
4:15 pm:
Abstract #902: Ablation of basophils reduces ILC2-dependent atopic dermatitis-like inflammation in mice overexpressing interleukin-33 in the skin.
5:03 pm:
Abstract #927: Peripheral nerves are involved in the development of Staphylococcus aureus-induced skin inflammation possibly via recruiting basophils.

CONCURRENT MINI-SYMPOSIUM 4
Skin of Color
3:15–5:45 pm in Conway
3:51 pm:

5:03 pm:
Abstract #1296: Gender and racial differences in patient perception of pruritus: Evidence from a single institution and National Ambulatory Medical Care Survey data. KA. Whang and SG. Kwatra. Baltimore, MD.

2018 INTERNATIONAL DERMATOEPIDEMIOLOGY ASSOCIATION (IDEA) MEETING
6–7:30 pm in St. John’s 24-25
6:40 pm: Abstract #269: Genetic ancestry does not influence atopic dermatitis susceptibility or disease activity among African Americans. Katrina Abuabara, MD, UCSF.

SANOFI GENZYME AND REGENERON PHARMACEUTICALS SYMPOSIUM
New Frontiers and Pivotal Investigation-Based Advances in the Pathoimmunobiology and Management of Atopic Dermatitis
6–7:30 pm in Panzacola F-3/4
6:00 pm: Emma Guttmann-Yassky, MD/PhD (Program Chair) Mount Sinai, New York, NY. The Translational Path for a Cytokine-Targeting Therapeutic Approach in Atopic Dermatitis
6:20 pm: Jonathan I. Silverberg, MD/PhD/MPH Northwestern University Feinberg School of Medicine, Chicago, IL. The Disease Burden, Quality-of-Life Impairment, and Comorbidities of AD and The Implications for Treatment for Patients with Moderate-to-Severe Disease
6:40 pm: Eric Simpson, MD Oregon Health and Science University, Portland, OR. The Therapeutic Landscape of Atopic Dermatitis: Th2 Targeting and Beyond
7:00 pm: Amy S. Paller, MD/MSc Northwestern University Feinberg School of Medicine, Chicago, IL. Bringing the Pathogenic Advances and Novel Treatments to Children with AD: What have we Learned?
7:20 pm: Emma Guttmann-Yassky, MD/PhD (Program Chair) The Disease Burden, Quality-of-Life Impairment, and Comorbidities of AD and Implications for Treatment for Patients with Moderate-to-Severe Disease— A Year 2018 Investigation-to-Application Update
7:25 pm: Interactive Question and Answer Session

FRIDAY, MAY 18, 2018
THE PEDIATRIC DERMATOLOGY RESEARCH ALLIANCE (PEDRA)/SOCIETY FOR PEDIATRIC DERMATOLOGY (SPD)
7-8:30 am in Conway
7:50 am:
Abstract #719: Abnormalities in skin barrier status correlate with autism in a murine model: could assessments of skin barrier function assist in early diagnosis of autism?
Peter Elias, MD, et al. Veteran Affairs Medical Center/University of California San Francisco
8 am:

Abstract #648: The barrier abnormality of early-onset pediatric atopic dermatitis results from abnormalities in tight junctions and epidermal lipids, but not differentiation proteins.
Patrick Brunner, MD, et al. The Rockefeller University

SATO PHARMACEUTICAL CO LTD, TOKYO JAPAN SATO SCIENTIFIC FORUM

Atopic Dermatitis - How our Increasing Understanding of Pathogenesis is Translating into New and Emerging Therapies
6:30 pm – 9:30 pm Conway
Amy S. Paller, MD/MSci Walter J. Hamlin Professor and Chair of Dermatology Professor of Pediatrics Director, Skin Disease Research Center Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

SATURDAY, MAY 19, 2018

OCULUS VIRTUAL REALITY SYMPOSIUM

New and Emerging Agents for the Management of Moderate-to-Severe Atopic Dermatitis in Adults: A Virtual Reality View
Noon–1:30 pm in Gatlin D-E
Symposium sponsored by an educational grant from Lilly
Steven R. Feldman, MD/PhD Wake Forest School of Medicine, Winston-Salem, NC

CONCURRENT MINI-SYMPOSIUM 13

Clinical Research: Patient Outcomes Research
3:15–5:45 pm in Panzacola F-3/4
3:39 pm:
Abstract #517: Effects of the oral janus kinase 1 (JAK1) inhibitor PF-04965842 on patient-reported outcomes (PROs) in adults with moderate to severe atopic dermatitis (AD).
E. Simpson, A. Wollenberg, R. Bissonnette, J. Silverberg, J. Papacharalambous, L. Zhu, W. Zhang, J. Beebe, M. Vincent, E. Peeva, A. Bushmakin, J. Cappelleri and L. Chen. Portland, OR; München, Bayern, Germany; Montreal, PQ, Canada; Chicago, IL; Groton, CT; Collegeville, PA; Cambridge, MA and New York, NY.

CONCURRENT MINI-SYMPOSIUM 16

Pharmacology and Drug Development
3:15–5:45 pm in Conway
3:27 pm:
Abstract #1071: Age-specific changes in the atopic dermatitis molecular phenotype.
4:27 pm:
Abstract #1075: From old king coal to novel therapeutics for inflammatory skin diseases: The aryl hydrocarbon receptor as a therapeutic target.

CONCURRENT MINI-SYMPOSIUM 18
Interdisciplinary Spotlight: Atopic Dermatitis
3:15–5:45 pm in Panzacola G-2
Presiders: Lawrence F. Eichenfield, MD, Mayumi Komine, MD, Nick Reynolds, MD
3:15 pm:
Abstract #404: Genetic variants in TLR1, TIRAP and PSAPL1 are enriched in a specific subgroup of adult atopic dermatitis showing persistent skin manifestation on the face and neck area.
3:27 pm:
Abstract #453: GBR 830 induces progressive and sustained changes in atopic dermatitis biomarkers in patient skin lesions.
3:39 pm:
Abstract #434: Baseline IL-22 expression in atopic dermatitis patients stratifies therapeutic responses to fezakinumab.
3:51 pm:
Abstract #554: The Janus kinase 1 (JAK1) inhibitor PF-04965842 reduces signs and symptoms of moderate to severe atopic dermatitis (AD).
M. Gooderham, S. Forman, R. Bissonnette, J. Beebe, W. Zhang, C. Banfield, L. Zhu, J. Papacharalambus, M. Vincent and E. Peeva. Peterborough, ON, Canada; Tampa, FL; Montreal, PQ, Canada and New York, NY.
4:03 pm:
Abstract #657: Characterisation of a novel murine model of atopic dermatitis.
4:15 pm:
Abstract #650: Suprabasin-deficient mice show limited but discernible defective barrier in both skin and upper digestive tract.
4:39 pm:
Abstract #234: Altered patterns of growth in infants with atopic eczema commence in-utero.

Abstract #264: Atopic dermatitis is associated with fragile homes in US children.
C. McKenzie and JI. Silverberg. Chicago, IL.

Abstract #920: Quorum sensing between bacterial species on skin protects against barrier disruption and inflammation promoted by Staphyloccocus aureus.
MR. Williams, JA. Sanford, T. Nakatsuji, AR. Horswill and R.L Gallo. La Jolla, CA; San Diego, CA, and Denver, CO.

Abstract #1066: Biomarkers CCL17/TARC and total IgE do not predict clinical response to dupilumab in atopic dermatitis (AD): A post hoc analysis of pooled phase 3 data (SOLO 1 & 2).
JD. Hamilton, Z. Chen, LA. Beck, EL. Simpson, T. Hultsch, NMH. Graham, G. Pirozzi, M. Ruddy and M. Ardeleanu. Tarrytown, NY; Rochester, NY; Portland, OR; Cambridge, MA; and Bridgewater, NJ.

POSTER AND EPOSTER SESSIONS

THURSDAY, MAY 17, 2018
POSTER SESSION I/COFFEE BREAK
11:45 am–1:45 pm in Gatlin A-C
• Poster #031: IgG from atopic dermatitis patients induces IL-17 and IL-10 production in infant intra-thymic TCD4 and TCD8 cells
• Poster #113: Epicutaneous allergen exposure induces pathogenic IL-22-producing T helper cells
• Poster #237: Validating self-reported atopic dermatitis in a large cohort of US women
• Poster #239: Physician experiences and perceptions of systemic therapies for atopic dermatitis in the United States
• Poster #245: Sleep disturbances in children with atopic dermatitis throughout childhood: A population-based longitudinal birth cohort study
• Poster #259: Uncommon filaggrin variants are associated with persistent atopic dermatitis in African-Americans
• Poster #269: Genetic ancestry does not influence atopic dermatitis susceptibility or disease activity among African Americans
• Poster #287: Impact of skin infections on medical expenditures in patients with atopic dermatitis
• Poster #341: Association between vitamin D and eczema among adults in the US National Health and Nutrition Examination Survey
• **Poster #345**: A real-world study evaluating ade:QUacy of existing systemic treatments for patients with moderate-to-severe atopic dermatitis (AD-QUEST): 6-month survey data on flares
• **Poster #381**: Association between peripheral eosinophil counts and atopic dermatitis severity in a longitudinal clinical cohort
• **Poster #427**: Efficacy of the topical application of collagen-derived dipeptide and Grifola frondosa extract for treating atopic dermatitis
• **Poster #534**: Perceptions of eczema in social media
• **Poster #556**: Patient-centered care: Clinical relevance of PROMIS domains in atopic dermatitis, acne, and psoriasis
• **Poster #634**: Skin ceramide profile in children with atopic dermatitis
• **Poster #648**: The barrier abnormality of early-onset pediatric atopic dermatitis results from abnormalities in tight junctions and epidermal lipids, but not differentiation proteins
• **Poster #654**: Epidermal pigmentation regulates cutaneous inflammation
• **Poster #664**: Atopic dermatitis: Linking skin barrier function with antioxidant defense
• **Poster #676**: Minimum role of filaggrin-gene mutations in the skin barrier function of atopic dermatitis
• **Poster #682**: Induction of keratin 1 and keratin 10 expression by topical glucose in a mouse model of atopic dermatitis and in keratinocyte culture: A possible role of glucose in skin barrier repair
• **Poster #684**: Aryl hydrocarbon receptor-dependent expression of aldo-keto reductase 1C3 in the pathogenesis of atopic dermatitis caused by air pollution
• **Poster #764**: miR-146a and miR-146b regulate members of the IL-1 family in human primary keratinocytes
• **Poster #882**: Toll-like receptor 1/2 ligand enhances IL-4 receptor signaling in human Langerhans cells
• **Poster #892**: Atopic dermatitis endotypes based on allergen sensitization, staphylococcus reactivity, and underlying systemic inflammation
• **Poster #950**: Severity of pediatric atopic dermatitis correlates to hemolytic potential of S. aureus isolates from atopic lesions
• **Poster #962**: Development of a novel humanized mouse model for atopic dermatitis
• **Poster #966**: The human cutaneous microbiome composition changes after coal tar treatment of both healthy and atopic dermatitis skin

**SELECTED EPOSTER DISCUSSIONS I**

**Clinical Research: Epidemiology of Skin Diseases**
12:15–1:15 pm in Gatlin Foyer Kiosk #2
12:57 pm:

**SELECTED EPOSTER DISCUSSIONS I**

**Epithelial Biology**
12:15–1:15 pm in Gatlin Foyer Kiosk #3
Abstract #647: Alternative splicing factor Esrp1 controls homeostasis of skins by regulating barrier formation and function.
S. Lee and R. Carstens. Philadelphia, PA.

SELECTED EPOSTER DISCUSSIONS I

Innate Immunity, Microbiology, Inflammation
12:15–1:15 pm in Gatlin Foyer Kiosk #4

Abstract #937: Keratinocyte alpha7 nicotinic acetylcholine receptor (CHRNA7) is the primary nicotinic receptor involved in impaired TLR2-dependent innate immunity: implications for AD pathogenesis and infection.

FRIDAY, MAY 18, 2018
COME SEE MY POSTER SESSION II
11:30–11:45 am in Gatlin D-E

Abstract #489: Dupilumab efficacy in atopic dermatitis in four randomized phase 3 trials (LIBERTY AD SOLO 1&2, CHROMOS, CAFE).
EL. Simpson, T. Bieber, M. de Bruin-Weller, A. Blauvelt, Z. Chen, M. Ardeleanu, B. Shumel, B. Akinlade and T. Hultsch. Portland, OR; Bonn, Germany; Utrecht, Netherlands; Tarrytown, NY and Cambridge, MA.

POSTER SESSION II/COFFEE BREAK
Noon–2 pm in Gatlin A-C
• Poster #022: Distinct transcriptome signature of skin-resident memory T cells and migratory memory T cells in atopic dermatitis
• Poster #032: Staphylococcus aureus enterotoxins modulate IL-22-secreting cells in adults with atopic dermatitis
• Poster #058: Variable TH2/TH17-skewing places Chinese atopic dermatitis and psoriasis on an inflammatory spectrum
• Poster #062: Involvement of β-catenin/CBP-dependent signaling in the emergence of hapten-induced atopic dermatitis-like dermatitis
• Poster #112: The IL-31-producing circulating T cells subset represents a unique population of CLA+ CRTH2+ CCR4+ central memory T cells
• Poster #282: Moderate to severe atopic dermatitis is associated with allergic, autoimmune and cardiovascular comorbidities in US adults
• Poster #288: Pain burden in atopic dermatitis
• Poster #294: A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis
• Poster #306: Racial disparities in medical visits among children with atopic dermatitis in the Pediatric Eczema Elective Registry
• **Poster #322**: Skin cancer risk among adults with atopic dermatitis exposed to topical calcineurin inhibitors
• **Poster #360**: Prenatal psychological stress and the risk of atopic dermatitis in offspring: a longitudinal birth cohort study
• **Poster #388**: A phase Ib trial in AD patients evaluating safety, tolerability, pharmacokinetics and efficacy of topical formulations containing the kappa-opioid receptor agonist WOL071-007
• **Poster #432**: Investigating a causal relationship between body mass index and inflammatory skin disease using mendelian randomisation
• **Poster #480**: Atopic dermatitis is an IL-13/IL10 driven disease with high molecular heterogeneity compared to psoriasis
• **Poster #1001**: Mast cells and microvasculature network expansion in asymptomatic atopic dermatitis
• **Poster #1015**: Effect of an emollient on the skin fungal microbiome of atopic dermatitis (AD) patients
• **Poster #1017**: Natural killer cell dysregulation underlies atopic dermatitis
• **Poster #1019**: Lack of skin mast cell activation and sphingosine-1-phosphate elevation in male mice may explain gender disparity observed in pre-symptomatic atopic dermatitis
• **Poster #1039**: Skin microbiome profiles of atopic dermatitis patients segregate into two community composition types that are stable before and after therapy
• **Poster #1069**: Minipig model of atopic dermatitis: Assessment of in vivo and in vitro activity of recombinant porcine interleukin-4 and interleukin-13
• **Poster #1083**: Effect of RVT-502 therapy in the NC/Nga mouse model of atopic dermatitis

**SATURDAY, MAY 19, 2018**
**POSTER SESSION III/COFFEE BREAK**
11:45 am–1:45 pm in Gatlin A-C
• **Poster #539**: Severity strata for POEM, PO-SCORAD and DLQI in a population-based sample of US adults with atopic dermatitis
• **Poster #589**: Use of electronic health record (EHR) tools and interactive didactics to empower pediatricians to manage atopic dermatitis (AD)
• **Poster #599**: Bringing therapeutic patient education in atopic dermatitis into the 21st century: a novel, low-cost, personalized, electronic health record-based framework
• **Poster #679**: Site-specific microarray evaluation of spontaneous dermatitis in flaky tail mice
• **Poster #695**: Protease-activated receptor 2 activation reduces Claudin-1 expression in primary human keratinocytes
• **Poster #743**: A new cellular pathway in hematopoiesis: 9-O-acetyl sialic acid levels identify committed progenitors of plasmacytoid dendritic cells
• **Poster #745**: Filaggrin gene (FLG) promoter polymorphisms are associated with atopic dermatitis but not ichthyosis vulgaris in Japan
• **Poster #757**: MiRNA signature in atopic dermatitis
• **Poster #929**: TH2 and TH17 cell differentiation is differentially regulated by innate anti-viral protein Trim32
• **Poster #949**: Skin microbiota alterations induce dysregulated IL-1α responses that drive atopic dermatitis-like skin inflammation

• **Poster #977**: TSLP promote FcRγ-associated receptors Overexpression on monocytes/MoDCs of patients with atopic dermatitis by TET2-mediating DNA demethylation

• **Poster #979**: Quantitative skin microbiome analysis identified new microbial species associated with atopic dermatitis

• **Poster #984**: Superoxide dismutase 3 controls Th2 cytokine-mediated allergic inflammation through inhibition of periostin

• **Poster #996**: Atopic dermatitis model on RHE in presence of S. aureus and infiltrating immuno-competent cells

• **Poster #1006**: Type 2 immune cells selectively interact with skin sensory nerve fibers in atopic dermatitis

• **Poster #1010**: Nummular eczema is a distinct clinical entity with overlapping features of both, psoriasis and atopic eczema

• **Poster #1020**: Assessment of the anti-inflammatory effects of cannabidiol and its fluorinated derivative in vitro and in vivo models of atopic dermatitis

• **Poster #1088**: Efficacy of AD-DER emollient in an in vitro atopic dermatitis model

• **Poster #1092**: Mechanism of action of Oligofructans from Ophiopogon japonicus to treat atopic dermatitis

• **Poster #1094**: Clinical pharmacokinetics and immunogenicity of GBR 830, a first-in-class humanized monoclonal antibody inhibiting OX40 to treat atopic dermatitis

• **Poster #1294**: Pediatric Atopic Dermatitis: A pilot comparative study across different races and ethnicities

**SELECTED EPOSTER DISCUSSIONS III**

**Immunology II**
12:15–1:15 pm in Gatlin Foyer Kiosk #4
12:15 pm:
**Abstract #083**: CXCR4-expressing skin-resident NKT cells develop allergic inflammation in atopic dermatitis.
Z. Sun, J. Kim, S. Kim, H. Kim, M. Ko, B. Kim, Y. Pan, C. Park, T. Kupper and K. Lee. Seoul, Republic of Korea; and Boston, MA.

**SELECTED EPOSTER DISCUSSIONS III**

**Epidermal Structure and Barrier Function**
12:15–1:15 pm in Gatlin Foyer Kiosk #2
12:27 pm:
**Abstract #652**: Peroxisomes contribute to inflammation in atopic dermatitis.